The UK hepatitis therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver and liver failure, which can be fatal. It is estimated that 113,000 people in England are living with chronic hepatitis C.
Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-coloured bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer. In UK, Hepatitis B and C affect millions of people.
An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the UK’s hepatitis therapeutics market. The introduction of generic versions of HCV drugs has changed the market dynamics across the world. With more people being able to afford the generic versions, the usage rates of its drugs are expected to grow rapidly over the next few year and as the accessibility of these drugs is a major issue among the low-income group, the generic cases are a saviour when it comes to the treatment of hepatitis in UK.
Almost 90% of hepatitis C cases in the UK occur in people who inject drugs or have injected them in the past. It is estimated around half of the people in the UK who inject drugs have the infection.
Infectious causes are further subdivided into viral, parasitic, and bacterial among which viral is the most common one.
Auto immune causes are further subdivided into Alcoholic, Toxic and drug induced as well as Non- alcoholic fatty lever disease.
It is a chronic disease caused by abnormal immune response against lever cells.
Genetic causes of hepatitis include alpha-1-antitrypsin deficiency, hemochromatosis, and Wilson’s disease and are hereditary.
It is characterized by reduced blood flow to lever because of shocks, vascular inefficiency or heat failure.